1000025-07-9
1000025-07-9
Chemical Structure
Vadadustat
Synonym(s): PG-1016548; AKB-6548
- CAS No.: 1000025-07-9
- Formula:C14H11ClN2O4
- Molecular Weight:306.70
IUPAC Name: (5-(3-chlorophenyl)-3-hydroxypicolinoyl)glycine
InChIKey: JGRXMPYUTJLTKT-UHFFFAOYSA-N
SMILES: O=C(O)CNC(C1=NC=C(C2=CC=CC(Cl)=C2)C=C1O)=O
Biological Activity: Vadadustat (PG-1016548) is a titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor[1]. Vadadustat is an erythropoiesis-stimulating agent and has the potential for anemia treatment in chronic kidney disease in vivo[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Vadadustat | 99.70% | Vadadustat (PG-1016548) is a titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. Vadadustat is an erythropoiesis-stimulating agent and has the potential for anemia treatment in chronic kidney disease in vivo. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Vadadustat (Standard) | 99.70% | Vadadustat (Standard) is the analytical standard of Vadadustat (HY-101277). This product is intended for research and analytical applications. Vadadustat (PG-1016548) is a titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. Vadadustat is an erythropoiesis-stimulating agent and has the potential for anemia treatment in chronic kidney disease in vivo. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Vadadustat-13C6 | Vadadustat-13C6 (PG-1016548-13C6) is 13C labeled Vadadustat. Vadadustat (PG-1016548) is a titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. Vadadustat is an erythropoiesis-stimulating agent and has the potential for anemia treatment in chronic kidney disease in vivo. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Pergola PE, et al. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 2016 Nov;90(5):1115-1122. [Content Brief]
- [2]. Gupta N, et al. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. Am J Kidney Dis. 2017 Feb 24. pii: S0272-6386(17)30110-5. [Content Brief]
